MXCT - MaxCyte GAAP EPS of -$0.08 in-line revenue of $9.6M beats by $0.37M August, 10 2022 04:22 PM MaxCyte Inc. MaxCyte press release ( NASDAQ: MXCT ): Q2 GAAP EPS of -$0.08 in-line. Revenue of $9.6M (+35.2% Y/Y) beats by $0.37M . For further details see: MaxCyte GAAP EPS of -$0.08 in-line, revenue of $9.6M beats by $0.37M